Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)
Evaluation of HIV protease inhibitor usage and the risk of sudden death or non-haemorrhagic stroke / S.W. Worm, D.A. Kamara, P. Reiss, E. Fontas, S. De Wit, W. El-Sadr, A. D’Arminio Monforte, M. Law, A. Phillips, L. Ryom, F. Dabis, R. Weber, C. Sabin, J.D. Lundgren, D:A:D Study Group. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - 205:4(2012 Feb 15), pp. 535-539.
Evaluation of HIV protease inhibitor usage and the risk of sudden death or non-haemorrhagic stroke
A. D’Arminio Monforte;
2012
Abstract
Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
